Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | The future of neuromodulation in movement disorders

Alfonso Fasano, MD, PhD, University of Toronto, Toronto, Canada, discusses the expanding field of neuromodulation and its immense potential for improving the lives of patients with movement disorders. Over the last few years, there has been a growing acceptance of neuromodulation as a viable treatment option, just like any other therapy. While the COVID-19 pandemic may have caused a temporary interruption, there is a resurgence in the use of neuromodulation techniques. Dr Fasano also predicts that adaptive stimulation and brain-spine interface will play an increasingly prominent role in the future. However, the main challenge lies in the cost associated with these treatments, which may limit accessibility, particularly in underprivileged regions. Therefore, there is a need to work on expanding availability and ensuring affordability as technology advances and alternative solutions emerge. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr Fasano reports the following disclosures:
Receipt of grants/research support: Boston Scientific, MJ Fox Foundation, Medtronic, University of Toronto, McLaughlin Centre
Receipt of honoraria or consultation fees: Abbott, Abbvie, American Academy of Neurology, Brainlab, Boston Scientific, Ceregate, Chiesi Farmaceutici, Inbrain, International Parkinson and Movement Disorder Society, Ipsen, Medtronic, Novartis, TEVA Canada, UCB pharma, Sunovion
Participation in a company sponsored advisory board: Abbott, Abbvie, Boston Scientific, Ipsen, Medtronic, Sunovion